Tumor News and Research

RSS

Tumor splicing burden predicts treatment response in kidney cancer

Researchers at City of Hope® and TGen (part of City of Hope) have identified a significant correlation between a tumor's "splicing burden" and its clinical response to treatment for metastatic renal cell carcinoma (mRCC).

5 May 2026

Hand-held wireless probe helps surgeons identify breast cancer tumors

Breast cancer impacts over 2 million women around the world each year. Following radiotherapy or chemotherapy, breast-conserving surgery is the first line of intervention for early-stage breast cancer.

5 May 2026

New technique uses electronic jolt and nanoparticles to reveal early signs of pancreatic cancer

Scientists at Oregon Health & Science University have developed a new technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer.

4 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

Cell division failure pathway determines fate after genome duplication

A new study shows that how a cell fails to divide after copying its DNA can determine its fate.

30 Apr 2026

Impaired protein recycling drives T cell exhaustion in cancer

T cells are crucial components of our immune system, serving as critical protectors against infection and disease.

30 Apr 2026

Pretargeted radioimmunotherapy shows promise for colorectal cancer treatment

A new pretargeted radioimmunotherapy (PRIT) technique has been shown to be safe and effective in eradicating tumors from a preclinical colorectal cancer model.

30 Apr 2026

Extracellular vesicles from T cells enhance tumor immune response

Activated immune cells secrete tiny capsules bearing DNA that can enter other immune and tumor cells to stimulate the body's defense systems, according to a study led by investigators at Weill Cornell Medicine.

30 Apr 2026

New CAR T cell design boosts persistence and reduces toxicity

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the infused cells fail to expand or persist.

30 Apr 2026

Liquid biopsy predicts immune response in high-risk breast cancer patients

Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors.

30 Apr 2026

Inflammation from leaking mitochondria drives aggressive pancreatic cancer growth

Scientists at The Wistar Institute and clinical researchers from ChristianaCare's Helen F. Graham Cancer Center & Research Institute have discovered a vulnerability in pancreatic cancer that could be targeted as a potential therapy.

30 Apr 2026

New spinal cord interface restores bladder control and sensation

Approximately 308,000 people in the United States live with spinal cord injury. Nearly all lose bladder control. And yet the vast majority of research and engineering attention in neurotech has poured into motor restoration-making paralyzed limbs move again.

30 Apr 2026

AI and CRISPR technologies drive proactive health monitoring

JMIR Publications today featured two new stories in its News and Perspectives section, highlighting a shift toward proactive, tech-integrated health monitoring.

30 Apr 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

Metabolic rewiring could help CAR-T cells fight solid tumors

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function.

29 Apr 2026

Researchers use light-activated nanozymes to treat aggressive brain tumors

Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack cancer cells directly in the brain during tumor surgery.

29 Apr 2026